KinderPharm Raises $1 Million to Further Advance Pediatric Drug DevelopmentKinderPharm, a full-service contract research organization (CRO) dedicated exclusively to pediatric drug development, has raised $1 million from a Series A, comprised of individuals, companies and angel investors. The $1 million investment will be used to further advance the clinical development of new medicines for children.
By: KinderPharm LLC EXTON, Pa. - Aug. 12, 2015 - PRLog -- Bringing Better Medicines to Children
The recently changed pharmaceutical industry’s perspective – as a result of legislative initiatives in both the US and Europe, and the increasing pressure from patients’ groups – created great opportunities for pediatric drug development. Our “Pediatric Center of Excellence” model is a unique resource of pediatricians, pharmacometricians, regulatory, drug safety and formulation scientists that develop pediatric drugs through all stages of development. Our seasoned teams bring expertise and insight to pharmaceutical companies of all sizes to help effectively navigate the complex pediatric regulatory environments in the US and Europe. With our partners we design, manage and conduct all aspects of pediatric product development including: Waivers and deferrals Age appropriate pediatric formulations Juvenile toxicology studies Protocol design Dose extrapolation PK/PD modeling and simulation Population PK/sparse sampling strategies PDP, PSP and PIP applications Pediatric clinical trials Regulatory strategy and submissions For further information, please contact: Martin Graham, PhD, Chief Executive Officer, (610) 458-1052 Janet Welsko, Chief Operating Officer, (610) 458-1052 Lynda Graham, MBA, Chief Financial Officer, (610) 458-1052 For media inquiries, please contact: Kristin Liezenga, Business Development Executive, (610) 458-1502 End
Account Email Address Account Phone Number Disclaimer Report Abuse
|